PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Watanabe, K.* ; Sato, E.* ; Mishima, E. ; Miyazaki, M.* ; Tanaka, T.*

What's new in the molecular mechanisms of diabetic kidney disease: Recent advances.

Int. J. Mol. Sci. 24:570 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease, including end-stage kidney disease, and increases the risk of cardiovascular mortality. Although the treatment options for DKD, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists, have advanced, their efficacy is still limited. Thus, a deeper understanding of the molecular mechanisms of DKD onset and progression is necessary for the development of new and innovative treatments for DKD. The complex pathogenesis of DKD includes various different pathways, and the mechanisms of DKD can be broadly classified into inflammatory, fibrotic, metabolic, and hemodynamic factors. Here, we summarize the recent findings in basic research, focusing on each factor and recent advances in the treatment of DKD. Collective evidence from basic and clinical research studies is helpful for understanding the definitive mechanisms of DKD and their regulatory systems. Further comprehensive exploration is warranted to advance our knowledge of the pathogenesis of DKD and establish novel treatments and preventive strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
5.600
0.000
9
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Sglt2 Inhibitor ; Diabetic Kidney Disease ; Fibrosis ; Hemodynamics ; Inflammation ; Metabolism; Glycation End-products; Mineralocorticoid Receptor Antagonists; Cotransporter 2 Inhibitors; Growth-factor-beta; Glomerular Hyperfiltration; Renal-insufficiency; Sglt2 Inhibitors; Clinical-trial; Double-blind; Activation
Sprache englisch
Veröffentlichungsjahr 2023
Prepublished im Jahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 1661-6596
e-ISSN 1422-0067
Zeitschrift International Journal of Molecular Sciences
Quellenangaben Band: 24, Heft: 1, Seiten: , Artikelnummer: 570 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Metabolism and Cell Death (MCD)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-506900-001
Förderungen
JSPS KAKENHI
DOI 10.3390/ijms24010570
WOS ID 000909239400001
WOS ID WOS:000909239400001
Scopus ID 85145975051
PubMed ID 36614011
Erfassungsdatum 2023-01-16
[➜Korrektur melden]